Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Gains from Sales and Divestitures: 2012-2013

  • Gyre Therapeutics' Gains from Sales and Divestitures fell 9.87% to $803,484 in Q4 2013 from the same period last year, while for Dec 2013 it was $803,484, marking a year-over-year decrease of 9.87%. This contributed to the annual value of $803,484 for FY2013, which is 9.87% down from last year.
  • Per Gyre Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $803,484 for Q4 2013, which was down 9.87% from $891,443 recorded in Q4 2012.
  • In the past 5 years, Gyre Therapeutics' Gains from Sales and Divestitures ranged from a high of $891,443 in Q4 2012 and a low of $803,484 during Q4 2013.
  • Its 2-year average for Gains from Sales and Divestitures is $847,464, with a median of $847,464 in 2012.
  • Data for Gyre Therapeutics' Gains from Sales and Divestitures shows a maximum YoY decreased of 9.87% (in 2013) over the last 5 years.
  • Quarterly analysis of 2 years shows Gyre Therapeutics' Gains from Sales and Divestitures stood at $891,443 in 2012, then decreased by 9.87% to $803,484 in 2013.